TRAXV
First Tracks Biotherapeutics Inc
Price Chart
Latest Quote
$22.51
Current Price| Open | $25.80 |
| Day High | $26.20 |
| Day Low | $22.50 |
| Volume | 20,877 |
Stock Information
| Shares Outstanding | 34.75M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $782.20M |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $17.24 |
| RSI | 50.39 |
| ATR | 1.9439 |
| Rel Volume | 1.15 |
Performance History
| Week | +15.49% |
| Month | -13.78% |
| YTD | -3.84% |
| 10 Years | -3.84% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-04 | $18.27 | 513,963 |
| 2026-06-03 | $15.32 | 554,897 |
| 2026-06-02 | $16.14 | 720,352 |
| 2026-06-01 | $18.09 | 854,741 |
| 2026-05-29 | $15.96 | 456,939 |
| 2026-05-28 | $15.82 | 298,223 |
| 2026-05-27 | $16.14 | 336,128 |
| 2026-05-26 | $17.06 | 290,822 |
| 2026-05-22 | $17.18 | 318,536 |
| 2026-05-21 | $16.76 | 307,275 |
| 2026-05-20 | $16.17 | 491,175 |
| 2026-05-19 | $16.66 | 509,015 |
| 2026-05-18 | $17.79 | 365,874 |
| 2026-05-15 | $16.90 | 196,058 |
| 2026-05-14 | $18.16 | 211,577 |
| 2026-05-13 | $18.43 | 301,909 |
| 2026-05-12 | $17.81 | 1,004,561 |
| 2026-05-11 | $18.76 | 345,550 |
| 2026-05-08 | $19.54 | 355,232 |
| 2026-05-07 | $17.82 | 542,671 |
| 2026-05-06 | $20.25 | 647,185 |
| 2026-05-05 | $21.19 | 342,599 |
About First Tracks Biotherapeutics Inc
First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incorporated in 2025 and is headquartered in San Diego, California. First Tracks Biotherapeutics, Inc. operates as a subsidiary of AnaptysBio, Inc.
đ° Latest News
No news articles available at the moment. Check back later for updates on TRAXV.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $0 | $0 |
| Operating Revenue | $0 | $0 |
| Expenses | ||
| Total Expenses | $181,101,000 | $118,461,000 |
| Other Income Expense | $14,000 | $-2,000 |
| Other Non Operating Income Expenses | $14,000 | $-2,000 |
| Net Non Operating Interest Income Expense | $17,382,000 | $12,313,000 |
| Operating Expense | $181,101,000 | $118,461,000 |
| General And Administrative Expense | $28,756,000 | $20,867,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-163,705,000 | $-106,150,000 |
| Net Interest Income | $17,382,000 | $12,313,000 |
| Interest Income | $17,382,000 | $12,313,000 |
| Normalized Income | $-163,705,000 | $-106,150,000 |
| Net Income From Continuing And Discontinued Operation | $-163,705,000 | $-106,150,000 |
| Total Operating Income As Reported | $-181,101,000 | $-118,461,000 |
| Net Income Common Stockholders | $-163,705,000 | $-106,150,000 |
| Net Income | $-163,705,000 | $-106,150,000 |
| Net Income Including Noncontrolling Interests | $-163,705,000 | $-106,150,000 |
| Net Income Continuous Operations | $-163,705,000 | $-106,150,000 |
| Pretax Income | $-163,705,000 | $-106,150,000 |
| Interest Income Non Operating | $17,382,000 | $12,313,000 |
| Operating Income | $-181,101,000 | $-118,461,000 |
| Per Share | ||
| Diluted EPS | - | $-3.05 |
| Basic EPS | - | $-3.05 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-178,704,000 | $-116,085,000 |
| Reconciled Depreciation | $2,397,000 | $2,376,000 |
| EBITDA (Bullshit earnings) | $-178,704,000 | $-116,085,000 |
| EBIT | $-181,101,000 | $-118,461,000 |
| Diluted NI Availto Com Stockholders | $-163,705,000 | $-106,150,000 |
| Research And Development | $152,345,000 | $97,594,000 |
| Selling General And Administration | $28,756,000 | $20,867,000 |
| Other Gand A | $28,756,000 | $20,867,000 |
| Diluted Average Shares | - | $34,748,841 |
| Basic Average Shares | - | $34,748,841 |
Fetched: 2026-05-07
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $391,596,000 | $409,849,000 |
| Total Assets | $441,891,000 | $444,109,000 |
| Total Non Current Assets | $51,958,000 | $45,554,000 |
| Other Non Current Assets | $256,000 | $256,000 |
| Current Assets | $389,933,000 | $398,555,000 |
| Prepaid Assets | $4,560,000 | $7,651,000 |
| Cash Cash Equivalents And Short Term Investments | $385,373,000 | $390,904,000 |
| Cash And Cash Equivalents | $123,080,000 | $35,965,000 |
| Debt | ||
| Total Debt | $16,037,000 | $17,814,000 |
| Long Term Debt And Capital Lease Obligation | $14,112,000 | $16,037,000 |
| Current Debt And Capital Lease Obligation | $1,925,000 | $1,777,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $50,295,000 | $34,260,000 |
| Total Non Current Liabilities Net Minority Interest | $14,112,000 | $16,037,000 |
| Current Liabilities | $36,183,000 | $18,223,000 |
| Payables And Accrued Expenses | $26,839,000 | $11,853,000 |
| Payables | $3,785,000 | $2,425,000 |
| Accounts Payable | $3,785,000 | $2,425,000 |
| Equity | ||
| Common Stock Equity | $391,596,000 | $409,849,000 |
| Total Equity Gross Minority Interest | $391,596,000 | $409,849,000 |
| Stockholders Equity | $391,596,000 | $409,849,000 |
| Gains Losses Not Affecting Retained Earnings | $305,000 | $-797,000 |
| Other | ||
| Ordinary Shares Number | $34,748,841 | $34,748,841 |
| Share Issued | $34,748,841 | $34,748,841 |
| Tangible Book Value | $391,596,000 | $409,849,000 |
| Invested Capital | $391,596,000 | $409,849,000 |
| Working Capital | $353,750,000 | $380,332,000 |
| Capital Lease Obligations | $16,037,000 | $17,814,000 |
| Total Capitalization | $391,596,000 | $409,849,000 |
| Capital Stock | $391,291,000 | $410,646,000 |
| Common Stock | $391,291,000 | $410,646,000 |
| Long Term Capital Lease Obligation | $14,112,000 | $16,037,000 |
| Current Capital Lease Obligation | $1,925,000 | $1,777,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $7,419,000 | $4,593,000 |
| Current Accrued Expenses | $23,054,000 | $9,428,000 |
| Investments And Advances | $35,470,000 | $27,026,000 |
| Net PPE | $16,232,000 | $18,272,000 |
| Accumulated Depreciation | $-6,599,000 | $-6,218,000 |
| Gross PPE | $22,831,000 | $24,490,000 |
| Leases | $203,000 | $203,000 |
| Other Properties | $21,098,000 | $22,647,000 |
| Machinery Furniture Equipment | $1,530,000 | $1,640,000 |
| Properties | $0 | $0 |
| Other Short Term Investments | $262,293,000 | $354,939,000 |
Fetched: 2026-05-07
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-126,164,000 | $-93,811,000 |
| Operating Activities | ||
| Operating Cash Flow | $-125,806,000 | $-93,004,000 |
| Cash Flow From Continuing Operating Activities | $-125,806,000 | $-93,004,000 |
| Investing Activities | ||
| Capital Expenditure | $-358,000 | $-807,000 |
| Investing Cash Flow | $95,398,000 | $144,754,000 |
| Cash Flow From Continuing Investing Activities | $95,398,000 | $144,754,000 |
| Financing Activities | ||
| Financing Cash Flow | $117,523,000 | $-87,093,000 |
| Cash Flow From Continuing Financing Activities | $117,523,000 | $-87,093,000 |
| Net Common Stock Issuance | $117,523,000 | $-87,093,000 |
| Other | ||
| End Cash Position | $123,080,000 | $35,965,000 |
| Beginning Cash Position | $35,965,000 | $71,308,000 |
| Changes In Cash | $87,115,000 | $-35,343,000 |
| Net Investment Purchase And Sale | $95,756,000 | $145,561,000 |
| Sale Of Investment | $476,132,000 | $449,480,000 |
| Purchase Of Investment | $-380,376,000 | $-303,919,000 |
| Net PPE Purchase And Sale | $-358,000 | $-807,000 |
| Purchase Of PPE | $-358,000 | $-807,000 |
| Change In Working Capital | $18,988,000 | $2,898,000 |
| Change In Other Current Liabilities | $-1,777,000 | $-1,636,000 |
| Change In Payables And Accrued Expense | $17,813,000 | $8,391,000 |
| Change In Payable | $17,813,000 | $8,391,000 |
| Change In Account Payable | $17,813,000 | $8,391,000 |
| Change In Prepaid Assets | $2,952,000 | $-3,857,000 |
| Stock Based Compensation | $26,827,000 | $18,393,000 |
| Amortization Of Securities | $-10,313,000 | $-10,521,000 |
| Depreciation Amortization Depletion | $2,397,000 | $2,376,000 |
| Depreciation And Amortization | $2,397,000 | $2,376,000 |
| Depreciation | $2,397,000 | $2,376,000 |
| Net Income From Continuing Operations | $-163,705,000 | $-106,150,000 |
Fetched: 2026-05-07